The Women’s Health Initiative showed that women on HRT had a higher risk of strokes and breast cancer (Manson et al, JAMA, Oct.2, 2013). During the five-year duration of the study, however, there was no difference in mortality between women taking HRT and those taking placebo. A recent report shows that after 18 years the participants still have no significant differences in mortality (Manson et al, JAMA, Sep. 12, 2017). Women like you who suffer during menopause often feel more comfortable taking estrogen (and progesterone, if indicated) during the time they need to suppress hot flashes. Experts usually recommend the lowest effective dose for the shortest possible time.
“Liquid biopsy” was able to detect tumours about 70% of the time on average in more than 1,000 patients with early-stage cancer. Crucially, it did so before the cancers had spread, giving patients the best chance of beating the disease.
Perfluorooctanoic acid, widely used for decades in the making of nonstick coatings like Teflon and a variety of other consumer products, is considered toxic even in tiny amounts. PFOA has been linked to cancer, birth defects and immune system dysfunction.
In 2006, eight major chemical companies, including 3M and DuPont, entered into a “voluntary stewardship agreement” with the US Environmental Protection Agency to phase out the production and use of PFOA by 2015. In its place, the industry switched to other chemicals in the same family that were deemed less hazardous by the EPA. But lately a variety of experts have begun to believe that these new chemicals also pose grave threats to human health. Remarkably, it’s not clear whether government regulators — or even companies like Saint-Gobain — know the specific chemical identities of the substances being substituted for PFOA.
Many complementary approaches — those used along with standard medical treatment — may be used to complement your doctor’s care and help you cope with the physical and mental toll of the disease. Together these approaches are often called complementary and alternative medicine (CAM), which describes many different products, approaches and treatments that are considered outside standard medical care.
Hormone replacement therapy (HRT) has twice been proven to cause cancer—once in 1975 and again in 2002. But you can’t expect Pharma to give up on a medication that 61 million women took until recently and that brought in $2 billion a year. Already articles promoting the dubious therapy are reappearing.
Many women who receive taxane-based chemotherapy to treat breast cancer experience long-term peripheral neuropathy, according to follow-up data from a large clinical trial.
Modern medicine offers several primary ways to treat breast cancer, including surgery, radiation, chemotherapy and anti-estrogen treatments. Ongoing investigations of immunotherapies may lead to their wider use in the future. If you’ve recently been diagnosed with breast cancer, your doctor may prescribe a combination of these treatment approaches depending on several factors, including the type and stage of your cancer. As with virtually every treatment currently available, both anti-estrogen drugs and immunotherapies can cause side effects in patients.
“We need to determine if 3-D mammography is better than 2-D at finding the sort of breast cancers that are most likely to spread and kill women,” said ECOG-ACRIN study chair Etta D. Pisano, M.D., vice chair of research in the Department of Radiology at Beth Israel Deaconess Medical Center and professor in residence of radiology at Harvard Medical School, Boston. “If a newer screening technology does not reduce the numbers of advanced, life-threatening cancers, then are we really improving screening for breast cancer?” TMIST researchers are collecting data on the results of every mammogram, whether the imaging shows no signs of cancer, findings suspicious of cancer, or a breast cancer. Any medical follow-ups, such as more imaging or biopsies, are also being reported. TMIST researchers intend to follow all participants for breast cancer status, treatment, and outcomes from the time of randomization until the end of the study (at least 2025).
Women who go up a skirt size every 10 years between their mid-20s and mid-60s are at 33% greater risk of developing breast cancer after the menopause, a study of more than 90,000 women finds.
While immunotherapies offer many promising things and come with the potential for incredible reward, they can also come with a cost. I think that caution is important as we begin dosing these new remedies in to countless more cancer patients in the hopes that they gain that ever-elusive cure just as my sister was able to do.
Researchers from the RUDN University have found out one of reasons why chemotherapy (in particular, cisplatin) gradually stops affecting the cells of ovarian and breast tumors. The authors study the biochemical mechanisms which allow tumor cells to develop resistance to antitumor drugs. During chemotherapy, when using certain drugs, the tumor cells are affected by toxic and oxidative stress, which stop their functioning. Sometime later, however, the cells “get used” to the drug action, which necessitates using stronger doses of the drug, which, in turn, negatively affects the patient’s organism due to its toxic effect.
Drinking water for more than 170 million Americans contains radioactive elements at levels that may increase the risk of cancer, according to an EWG analysis of 2010 to 2015 test results from public water systems nationwide.
Women who have had breast cancer treatment may be at increased risk for osteoporosis and fracture. Estrogen has a protective effect on bone, and reduced levels of the hormone trigger bone loss. Because of treatment medications or surgery, many breast cancer survivors experience a loss of ovarian function and, consequently, a drop in estrogen levels. Women who were premenopausal before their cancer treatment may go through menopause earlier than those who have not had breast cancer. Results from the NIH-supported Women’s Health Initiative Observational Study (WHI-OS) found an increase in fracture risk among breast cancer survivors.
Exfoliants may be great for your skin, but the environment is paying a high price thanks to one tiny ingredient in your soap: microbeads.
Plastics seem to invade every aspect of our lives, and the kitchen is no exception. From cooking to storage to packing food for on the go, there are places that we can ditch the plastic in favor of safer, more Earth-friendly materials. Take some time to inventory the plastic in your kitchen and see if your kitchen can go plastic-free. It’s easier than you think!
Working with your doctor when you have metastatic breast cancer: Interview with a Mayo Clinic expert
Hearing your doctor tell you that you’ve got metastatic breast cancer can be shocking. Once you’ve had a chance to gather your thoughts, make time to have a conversation with your health care provider and your loved ones about next steps.
Discussing treatment goals is a critical conversation to have with your health care provider and loved ones
Women who fasted for less than 13 hours a night had a 36% higher risk for breast cancer recurrence, compared with those who fasted for 13 or more hours. No link emerged between shorter fasting time and death from breast cancer or mortality from any other cause. Patients with early stage breast cancer who fasted for longer had significantly lower concentrations of HbA1c and longer sleep duration.
Most people receiving chemotherapy will begin seeing a limited amount of thin, fuzzy hair a few weeks after their last treatment. Real hair starts to grow properly within a month or two of the last treatment. A small fraction of people who are given chemotherapy may never regrow their hair. Specific drugs increase the risk of permanent hair loss. The breast cancer drug docetaxel, which is sold under the brand name Taxotere, has been known to cause permanent hair loss in some people.
Many women who receive taxane-based chemotherapy to treat breast cancer experience long-term peripheral neuropathy, according to follow-up data from a large clinical trial. Two years after the start of treatment, more than 40% of participants in the trial said they still experienced numbness and tingling in their hands or feetExit Disclaimer, and 10% rated their symptoms as severe. Patients with severe neuropathy reported lower quality of life than patients without severe symptoms.
Because of its wide use and potential harm, 1,4-dioxane is one of the first 10 chemicals the Environmental Protection Agency picked for review under the nation’s new chemical safety law. But the review could take years, and even then there’s no guarantee the EPA will do anything: The agency has failed to set standards for any new drinking water contaminant in more than 20 years.